PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Folinic Acid→

Folinic Acid PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
58-05-9
Molecular formula
C20H23N7O7
Molecular weight
473.4 g/mol
Drug class
Leucovorin (5-formyltetrahydrofolate)reduced folate analogue and folate rescue agent
Mechanism of action
Provides reduced folate downstream of dihydrofolate reductase, bypassing DHFR blockade and restoring tetrahydrofolate pools. It also potentiates fluorouracil by stabilising the thymidylate synthase–FdUMP complex.
Indications / reported uses
  • Rescue after high-dose methotrexate therapy and treatment of folate-antagonist toxicity
  • In combination with fluorouracil to enhance antitumour activity in colorectal cancer regimens
  • Treatment of selected megaloblastic anaemias due to folate deficiency when parenteral therapy is needed; not a substitute for folic acid in routine prevention

Sources: US DailyMed — Leucovorin calcium · NLM MeSH — Folinic acid · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Folinic Acid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Folinic Acid Permitted Daily Exposure (PDE) report (the Folinic Acid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Folinic Acid Occupational Exposure Limit (OEL) report (the Folinic Acid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.